CLINICAL TRIALS PROFILE FOR PSILOCYBIN

Clinical Trials for Psilocybin

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00302744 ↗	Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety	Completed	Heffter Research Institute	Phase 1	Psychiatric Research Study For Cancer Patients The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center is conducting a study designed to measure the effectiveness of the novel psychoactive medication psilocybin on the reduction of anxiety, depression, and physical pain.
NCT00302744 ↗	Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety	Completed	Los Angeles Biomedical Research Institute	Phase 1	Psychiatric Research Study For Cancer Patients The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center is conducting a study designed to measure the effectiveness of the novel psychoactive medication psilocybin on the reduction of anxiety, depression, and physical pain.
NCT00302744 ↗	Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety	Completed	Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	Phase 1	Psychiatric Research Study For Cancer Patients The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center is conducting a study designed to measure the effectiveness of the novel psychoactive medication psilocybin on the reduction of anxiety, depression, and physical pain.
NCT00465595 ↗	Psychopharmacology of Psilocybin in Cancer Patients	Completed	Heffter Research Institute	Phase 2	This research is being done to study the psychological effects of psilocybin in cancer patients. Psilocybin is a naturally occurring substance found in some mushrooms that some cultures have used for centuries in religious practices.
NCT00465595 ↗	Psychopharmacology of Psilocybin in Cancer Patients	Completed	Johns Hopkins University	Phase 2	This research is being done to study the psychological effects of psilocybin in cancer patients. Psilocybin is a naturally occurring substance found in some mushrooms that some cultures have used for centuries in religious practices.
NCT00465595 ↗	Psychopharmacology of Psilocybin in Cancer Patients	Completed	Sidney Kimmel Comprehensive Cancer Center	Phase 2	This research is being done to study the psychological effects of psilocybin in cancer patients. Psilocybin is a naturally occurring substance found in some mushrooms that some cultures have used for centuries in religious practices.
NCT00802282 ↗	Psilocybin and Spiritual Practice	Completed	Fetzer Institute	Phase 1	This study will investigate the effects of psilocybin dose and the frequency and intensity of support activities for spiritual practice (e.g., meditation) on a battery of attitudinal and behavioral outcome measures in 75 healthy volunteers who are interested in pursuing a program of spiritual practices with the intention applying spiritual insights and knowledge to everyday life. After screening and study enrollment, each volunteer will be assigned to one of five groups that vary in dose, frequency and intensity of support for spiritual practice, and number of psilocybin sessions (either 2 or 3 sessions). The psilocybin dose manipulation will be double-blind. Volunteers will be told that in each of sessions 1, 2, and 3, he/she could receive a very low, low, moderate, moderately high, or high dose of psilocybin. They will be told that each participant will receive 2 or more dose levels of psilocybin over the 2 or 3 sessions, and all participants will have one or more sessions in which he or she receives a moderately high or high dose of psilocybin. The duration of each volunteer's participation will be approximately 6 to 8 months. Each volunteer will receive several hours of preparation with the study guides in the month prior to the first psilocybin session; the first two sessions will be separated by one month. Various measures will be assessed before, during and immediately after sessions. A battery of longitudinal measures will be evaluated immediately after study enrollment, 3 weeks after the second psilocybin session, and 4 months after the second psilocybin session (6 months after study enrollment). For purposes of controlling expectancies through the 6 month follow-up evaluation, volunteers and guides will not know which volunteers or how many volunteers will be scheduled for a third session.

Clinical Trial Conditions for Psilocybin

Condition Name

Condition Name
Intervention	Trials
Healthy	21
Major Depressive Disorder	15
Depression	10
Treatment Resistant Depression	10

Condition MeSH

Condition MeSH
Intervention	Trials
Depression	35
Depressive Disorder	33
Disease	21
Depressive Disorder, Major	19

Clinical Trial Locations for Psilocybin

Trials by Country

Trials by Country
Location	Trials
United States	93
Switzerland	13
Canada	12
United Kingdom	11
Denmark	4

Trials by US State

Trials by US State
Location	Trials
Maryland	23
California	15
Connecticut	9
New York	8
Wisconsin	8

Clinical Trial Progress for Psilocybin

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	2
Phase 2/Phase 3	1
Phase 2	65

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Not yet recruiting	64
Recruiting	49
Completed	14

Clinical Trial Sponsors for Psilocybin

Sponsor Name

Sponsor Name
Sponsor	Trials
Johns Hopkins University	21
Heffter Research Institute	13
COMPASS Pathways	13

Sponsor Type

Sponsor Type
Sponsor	Trials
Other	230
Industry	31
NIH	6